PBS updates

Zydelig (Idelalisib)

idelalisib 100 mg tablet, 60 · ORAL · PBS code 11170X

AUTHORITY_REQUIRED

What it costs

AU$4956.86 PBS-determined price per 60 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2017-09-01.
  • • Repeats: 5.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)


Initial treatment


The condition must be confirmed Chronic lymphocytic leukaemia (CLL) prior to initiation of treatment; or

The condition must be confirmed Small lymphocytic lymphoma (SLL) prior to initiation of treatment; AND

Patient must not have previously received PBS-subsidised treatment with this drug for this condition; AND

The treatment must be in combination with rituximab for up to a maximum of 8 doses under this restriction, followed by monotherapy for this condition; AND

The condition must have relapsed or be refractory to at least one prior therapy; AND

The condition must be CD20 positive; AND

The treatment must only be prescribed for a patient with active disease in accordance with the International Workshop on CLL (iwCLL) guidance (latest version) in relation to when to prescribe drug treatment for this condition; AND

Must be treated by a medical practitioner.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)


Continuing treatment


Patient must have previously received PBS-subsidised treatment with this drug for Chronic lymphocytic leukaemia; or

Patient must have previously received PBS-subsidised treatment with this drug for Small lymphocytic leukaemia; AND

Patient must not develop disease progression while receiving PBS-subsidised treatment with this drug for this condition; AND

Must be treated by a medical practitioner; or

Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.

Sponsor: Gilead Sciences Pty Limited ABN 71 072 611 708

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.